Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance

Gemcitabine and carboplatin/cisplatin (“platinum”)-based combinations are used to treat a wide variety of malignancies including gynecologic, breast, lung, and occult primary cancers. In Non-Small Cell Lung Cancer (NSCLC), these combinations led to a substantial improvement in overall survival. Nevertheless, a large proportion of patients do not respond. An optimal cytotoxic strategy for managing NSCLC and the discovery of predictive biomarkers for cytotoxic chemotherapy to guide treatment selection remain unmet needs in the clinic. The Cellworks Computational Omics Biology Model (CBM) platform identified a unique chromosomal signature which permits a stratification of patients that are most likely to respond to gemcitabine and platinum treatments. Journal of Thoracic Oncology 2021 Non-Small Cell Lung Cancer